Progress in treatment of anti-hepatitis B virus drug nucleoside analogues in preventing mother-to-child transmission

Author: Zhou-Song ZHENG ¹ ; Yan HUANG ² ; Ze-Bing HUANG ²
Author Information

1. Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University
2. National Clinical Research Center for Geriatrics, Central South University, Xiangya Hospital, Dept of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan Province
Publication Type:Journal Article
Keywords: chronic hepatitis B; efficacy; nucleoside analogues; prevention of mother-to-child transmission; safety; treatment progress
From: Chinese Pharmacological Bulletin 2023;39(12):2221-2224
CountryChina
Language:Chinese
Abstract: Mother-to-child transmission of hepatitis B virus (HBV) is one of the main ways of transmission and the main cause of chronic hepatitis B after infection. Therefore, preventing mother-to-child transmission of HBV is particularly important in reducing the incidence of chronic hepatitis B. Currently, nucleoside ( acid) analoids ( Nas ) used for mother-to-child blocking of HBV include lamivudine (LAM) , tibivudine (LdT) and tenofovir fumarate ( TDF). Propofol tenofovir fumarate (TAF) has also been used in pregnant chronic hepatitis B pa- tients. This paper summarizes the efficacy, safety and antiviral treatment indications and termination time of the above-mentioned drugs in mother-to-child preventing to provide suggestions for the selection and rational application of mother-to-child preventing Nas.